Ascend Capital’s Coherus Oncology CHRS Stock Holding History

Ascend Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-60,000	Closed	-$1.69M	–	147
2016 Q4	$1.69M	Buy	+60,000	New	+$1.68M	0.08%	124

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ascend Capital's CHRS Position: Q1 2017 in Review

Ascend Capital sold out of Coherus Oncology (CHRS) in Q1 2017, closing a stake of 60,000 shares — an estimated $1.69M sold.

Ascend Capital first reported a position in CHRS in Q4 2016 and held it in 1 quarter. The position peaked at $1.69M in Q4 2016. 109 funds tracked by Wall St. Rank hold CHRS as of Q1 2017.

Ascend Capital reported no remaining Coherus Oncology position as of Q1 2017 after selling out during the quarter.
Ascend Capital sold 60,000 Coherus Oncology shares in Q1 2017, an estimated $1.69M.
Ascend Capital first reported a position in Coherus Oncology in Q4 2016 and held it in 1 quarter.
Ascend Capital's Coherus Oncology position peaked at $1.69M in Q4 2016.
109 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2017.

Based on Ascend Capital's 13F filing for Q1 2017, filed 15 May 2017.